Status:
UNKNOWN
Lidocaine Spray 10% Versus Oral Ibuprofen Tablets in Pain Control During Copper Intrauterine Device Insertion
Lead Sponsor:
Marina Ramsis Aziz Ghaly
Conditions:
Lidocaine Toxicity
Eligibility:
FEMALE
Phase:
NA
Brief Summary
The intrauterine contraceptive device (IUD) is the most commonly used form of reversible contraception worldwide; the predominant type of product, the copper IUD (a plastic T-shaped device with copper...
Detailed Description
The aim of this study is to This study is designed to compare between lidocaine spray 10% and oral ibuprofen as an adequate method for decreasing pain during copper intrauterine contraceptive device i...
Eligibility Criteria
Inclusion
- Multiparous women in 3rd to 5th day of menstrual cycle 2- Women who were 6 weeks postpartum or if recently pregnant. 3- Accept to participate and provide consent
Exclusion
- • A contraindication for IUD use such as a gynecological malignancy , sexually transmitted diseases, pelvic inflammatory disease or undiagnosed abnormal vaginal bleeding.
- Suspicion of pregnancy .
- Allergy to lidocaine or ibuprofen .
- Copper allergy .
- Any uterine abnormalities distorted uterine cavity as congenital anomalies, endometrial lesions, adenomyosis , and submucous myoma.
- A psychological or neurological disorder associated with altered pain sensation.
- MIRENA insertion.
- Nulliparity.
- History of failed intrauterine device insertion (uterine perforation, acute expulsion).
Key Trial Info
Start Date :
December 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 10 2023
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT05241496
Start Date
December 15 2021
End Date
October 10 2023
Last Update
July 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AinSHAMS UNIV
Cairo, Egypt, 11531